Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma

Molecular Cancer Therapeutics

Volumn 6, Issue 9, 2007, Pages 2554-2562

  Kim, Won ^a   Yoon, Jung Hwan ^a,d   Jeong, Jae Min ^b   Cheon, Gi Jeong ^c   Lee, Tae Sup ^c   Yang, Jong In ^a   Park, Su Cheol ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; DEOXYCHOLIC ACID; DNA NUCLEOTIDYLEXOTRANSFERASE; ENZYME INHIBITOR; HEXOKINASE; HEXOKINASE ISOENZYME; HYDRAZINONICOTINAMIDE TC 99M; LIPOCORTIN 5; PYRUVIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C3H MOUSE; CANCER CELL CULTURE; CANCER GROWTH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOPRECIPITATION; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANNEXIN A5; ANOXIA; APOPTOSIS; AZIRINES; CARCINOMA, HEPATOCELLULAR; ENZYME INHIBITORS; FLOW CYTOMETRY; HEXOKINASE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MITOCHONDRIA; PHOSPHATIDYLCHOLINES; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 34748922322     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0115     Document Type: Article

References (49)

1. Liang TJ, Jeffers LJ, Reddy KR, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993;18:1326-33.
2. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-80.
3. Koike K. Role of hepatitis viruses in multistep hepatocarcinogenesis. Dig Liver Dis 2001;33:2-6.
4. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8.
5. Bottelli R, Tibballs J, Hochhauser D, Watkinson A, Dick R, Burroughs AK. Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol 1998;53:713-6.
6. Cedrone A, Covino M, Caturelli E, et al. Utility of α-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000;47:1654-8.
7. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002;62 Suppl 1:64-8.
8. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.
9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
10. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
11. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88.
12. Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationshipwith demographic, environmental, and clinical factors. Cancer 1993;72:1557-63.
13. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003;18:189-95.
14. Sawabe M, Nakamura T, Kanno J, Kasuga T. Analysis of morphological factors of hepatocellular carcinoma in 98 autopsy cases with respect to pulmonary metastasis. Acta Pathol Jpn 1987;37:1389-404.
15. Matsunaga T, Shirasawa H, Hishiki T, et al. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior. Jpn J Cancer Res 1998;89:1276-83.
16. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898-907.
17. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001;116:838-45.
18. Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol 2003;38:793-802.
19. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 1977;74:3735-9.
20. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981;256:8699-704.
21. Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res 1988;48:913-9.
22. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995;270:16918-25.
23. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005;42:358-64.
24. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92:1042-53.
25. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
26. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-31.
27. Brenner C, Cadiou H, Vieira HL, et al. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene 2000;19:329-36.
28. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002;277:7610-8.
29. Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 2003;10:1535-51.
30. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004;324:269-75.
31. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38610-8.
32. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63.
33. Yamashita YI, Shimada M, Hasegawa H, et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001;61:1005-12.
34. Hensel R, Mayr U, Woenckhaus C. Affinity labelling of the allosteric site of the L-lactate dehydrogenase of Lactobacillus casei. Eur J Biochem 1983;135:359-65.
35. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21.
36. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-8.
37. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 1998;95:6349-54.
38. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995;272:930-8.
39. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
40. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005;65:10545-54.
41. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255:357-60.
42. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor α-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998;18:6353-64.
43. Hatano E, Bradham CA, Stark A, Iimuro Y, Lemasters JJ, Brenner DA. The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. J Biol Chem 2000;275:11814-23.
44. Marzo I, Brenner C, Zamzami N, et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J Exp Med 1998;187:1261-71.
45. Belzacq AS, Vieira HL, Kroemer G, Brenner C. The adenine nucleotide translocator in apoptosis. Biochimie 2002;84:167-76.
46. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-76.
47. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 1997;414:253-7.
48. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909-13.
49. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol Med 2005;111:363-80.